Shots:
- The US FDA has approved Cosentyx(secukinumab) for the treatment of pts (≥12yrs., ≥30kg) with mod. to sev. hidradenitis suppurativa
- Approval was supported by adult clinical studies, PK modeling extrapolated from adult HS & psoriasis trials, pediatric trial data from other approved indications, & dosing analyses that showed weight-based pediatric dosing achieves exposure comparable to adults
- Cosentyx is a fully human biologic that blocks interleukin-17A, a key driver of inflammation in various immune-mediated diseases
Ref: Novartis | Image: Novartis | Press Release
Related News: Novartis AG to Transfer Stake in Novartis India Limited to ChrysCapital
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
